48

Becton Dickinson (BDX-N)

ON STOCKCHASE SINCE May 2003

disposable medical supplies

biotechnology/pharmaceutical

Becton Dickinson
BDX-N

31 watching

Join the Discussion

Expert Opinions
0 comments
Your Reaction

0 0 0 0 0

What the experts are saying about BDX-N

Signal	Opinion	Expert
DON'T BUY	Becton Dickinson(BDX-N) January 31, 2019 They made a huge acquisition a few years ago and took on debt. They are OK financially but they overpaid for the company. He prefers other areas in the Health Care space. It is a big question mark how they integrate this company. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	They made a huge acquisition a few years ago and took on debt. They are OK financially but they overpaid for the company. He prefers other areas in the Health Care space. It is a big question mark how they integrate this company. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Lorne Steinberg President , Lorne Steinberg Weal... Price $249.460 Owned Unknown

PAST TOP PICK	Becton Dickinson(BDX-N) January 22, 2019 (A Top Pick Jan 04/18, Up 10%) They had a tremendous catalogue of hospital supplies, mostly one-time use items. Every hospital uses their stuff. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	(A Top Pick Jan 04/18, Up 10%) They had a tremendous catalogue of hospital supplies, mostly one-time use items. Every hospital uses their stuff. biotechnology/pharmaceutical 0 0 0 0 0 0 comments David Baskin President, Baskin Wealth Manage... Price $239.190 Owned Yes
HOLD	Becton Dickinson(BDX-N) January 17, 2019 Has been around for 100 years. Valuation is 15x earnings for 2021. Stock jumped today. Big free cash flow company. Made an acquisition of Bard, another free cash flow giant, so they're paying down debt quickly. So they'll have cash to make acquisitions or grow dividend. In comparing retail to medical devices, he'd always pick the medical device company. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Has been around for 100 years. Valuation is 15x earnings for 2021. Stock jumped today. Big free cash flow company. Made an acquisition of Bard, another free cash flow giant, so they're paying down debt quickly. So they'll have cash to make acquisitions or grow dividend. In comparing retail to medical devices, he'd always pick the medical device company. biotechnology/pharmaceutical 0 0 0 0 0 0 comments David Driscoll President , Liberty Internationa... Price $236.110 Owned Yes
TOP PICK	Becton Dickinson(BDX-N) January 17, 2019 The oldest manufacturer of syringes and other medical devices. There is good growth in emerging countries. They will pay down debt and have attractive dividend growth. (Analysts’ price target is $263.10) biotechnology/pharmaceutical 0 0 0 0 0 0 comments	The oldest manufacturer of syringes and other medical devices. There is good growth in emerging countries. They will pay down debt and have attractive dividend growth. (Analysts’ price target is $263.10) biotechnology/pharmaceutical 0 0 0 0 0 0 comments Michael Simpson Senior Vic, Sentry Investments... Price $236.110 Owned Yes
HOLD	Becton Dickinson(BDX-N) January 7, 2019 Has owned for a while. One of the more defensive companies you can own. Medical things you can only use once. Sells a suite of products and software to hospitals. Lots of EM opportunities. Still has to pay down debt from an acquisition, but but in 12-18 months should be ready for another. Good place to be with aging demographics, especially in US. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Has owned for a while. One of the more defensive companies you can own. Medical things you can only use once. Sells a suite of products and software to hospitals. Lots of EM opportunities. Still has to pay down debt from an acquisition, but but in 12-18 months should be ready for another. Good place to be with aging demographics, especially in US. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Barry Schwartz CIO & Port, Baskin Wealth Manage... Price $218.640 Owned Yes
WATCH	Becton Dickinson(BDX-N) December 3, 2018 Merely an okay last quarter with cost increases and more debt after an acquisition. Resin cost inputs are worth watching. Trades at 18x earnings. Watching this closely. Neutral. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Merely an okay last quarter with cost increases and more debt after an acquisition. Resin cost inputs are worth watching. Trades at 18x earnings. Watching this closely. Neutral. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Paul Macdonald Chief Inve, Harvest Portfolios G... Price $252.560 Owned No
PAST TOP PICK	Becton Dickinson(BDX-N) November 12, 2018 (A Top Pick Nov 07/17, Up 10%) Their big thing is drug delivery equipment. They have a lot of things going for them. They had a messy quarter. It is why he prefers to use ETFs for this. It was not a small pull back for them. The acquisition gives them some synergy on costs. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	(A Top Pick Nov 07/17, Up 10%) Their big thing is drug delivery equipment. They have a lot of things going for them. They had a messy quarter. It is why he prefers to use ETFs for this. It was not a small pull back for them. The acquisition gives them some synergy on costs. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Cameron Hurst Chief Inve, Equium Capital Manag... Price $236.220 Owned Yes
TOP PICK	Becton Dickinson(BDX-N) November 2, 2018 They make medical devides (syringes, blood test equipment). After last year's acqusition, there are two cash-flow companies here which excites him. He's owned this for a decade. 1.3% dividend. 10% dividend and price growth. (Analysts’ price target is $270.50) biotechnology/pharmaceutical 0 0 0 0 0 0 comments	They make medical devides (syringes, blood test equipment). After last year's acqusition, there are two cash-flow companies here which excites him. He's owned this for a decade. 1.3% dividend. 10% dividend and price growth. (Analysts’ price target is $270.50) biotechnology/pharmaceutical 0 0 0 0 0 0 comments David Driscoll President , Liberty Internationa... Price $235.580 Owned Yes
PAST TOP PICK	Becton Dickinson(BDX-N) October 31, 2018 (A Top Pick Aug 29/18, Up 18%) They do healthcare--hospitals, clinics--as an end-to-end service provider. They give hospital admin the software and provide all the products you'd need, like catheters or surgical equipment. Really they have no competition. Their customers stay loyal. They made a recent acquisition that gives them more international exposure. It doesn't have as much regulatory risk as other healthcare or pharma companies. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	(A Top Pick Aug 29/18, Up 18%) They do healthcare--hospitals, clinics--as an end-to-end service provider. They give hospital admin the software and provide all the products you'd need, like catheters or surgical equipment. Really they have no competition. Their customers stay loyal. They made a recent acquisition that gives them more international exposure. It doesn't have as much regulatory risk as other healthcare or pharma companies. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Barry Schwartz CIO & Port, Baskin Wealth Manage... Price $230.500 Owned Yes
PAST TOP PICK	Becton Dickinson(BDX-N) August 24, 2018 (A top pick June 6/18, up 10%) This stock is showing no signs of consolidation and is in an uptrend. So is continuing to hold it. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	(A top pick June 6/18, up 10%) This stock is showing no signs of consolidation and is in an uptrend. So is continuing to hold it. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Keith Richards Portfolio , ValueTrend Wealth Ma... Price $255.400 Owned Yes
TOP PICK	Becton Dickinson(BDX-N) June 6, 2018 A great up trending stock chart. It is consolidating at the moment with lots of time to grow. Yield 1.3%. (Analysts’ price target is $251.11) biotechnology/pharmaceutical 0 0 0 0 0 0 comments	A great up trending stock chart. It is consolidating at the moment with lots of time to grow. Yield 1.3%. (Analysts’ price target is $251.11) biotechnology/pharmaceutical 0 0 0 0 0 0 comments Keith Richards Portfolio , ValueTrend Wealth Ma... Price $231.610 Owned Yes
BUY	Becton Dickinson(BDX-N) April 23, 2018 U.S. healthcare in the short-term? He prefers individual stocks over ETFs, starting with Becton Dickinson (and Zimmer Biomet, ZBH-N). In this sector, he prefers medical devices, not drugs which are easy to copy. Becton is a long-term opportunity and a play on demographics. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	U.S. healthcare in the short-term? He prefers individual stocks over ETFs, starting with Becton Dickinson (and Zimmer Biomet, ZBH-N). In this sector, he prefers medical devices, not drugs which are easy to copy. Becton is a long-term opportunity and a play on demographics. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Barry Schwartz CIO & Port, Baskin Wealth Manage... Price $233.020 Owned Yes
PAST TOP PICK	Becton Dickinson(BDX-N) March 28, 2018 (A Top Pick May 19/17, Up 17%) They merged with C.R. Bard, another medical device company, so this has opened doors for them internationally. Dividend growing 10% a year. They continue to acquire and grow. He has owned it for 10 years. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	(A Top Pick May 19/17, Up 17%) They merged with C.R. Bard, another medical device company, so this has opened doors for them internationally. Dividend growing 10% a year. They continue to acquire and grow. He has owned it for 10 years. biotechnology/pharmaceutical 0 0 0 0 0 0 comments David Driscoll President , Liberty Internationa... Price $212.430 Owned Yes
PARTIAL BUY	Becton Dickinson(BDX-N) February 21, 2018 He sees this as a good company, but not in his top 25. Healthcare technology has been very profitable and medical consumables is a niche area. There is good opportunity to grow through value add like prefilled syringes. He sees them as a high quality, low cost provider. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	He sees this as a good company, but not in his top 25. Healthcare technology has been very profitable and medical consumables is a niche area. There is good opportunity to grow through value add like prefilled syringes. He sees them as a high quality, low cost provider. biotechnology/pharmaceutical 0 0 0 0 0 0 comments David Fingold VP and Por, Dynamic Funds... Price $218.700 Owned Yes
BUY	Becton Dickinson(BDX-N) February 13, 2018 They bought C.R. Bard, the Canadian Tire of medical supplies and basically consolidated the industry, giving them tremendous market share and pricing power. They are now the premier company in this space. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	They bought C.R. Bard, the Canadian Tire of medical supplies and basically consolidated the industry, giving them tremendous market share and pricing power. They are now the premier company in this space. biotechnology/pharmaceutical 0 0 0 0 0 0 comments David Baskin President, Baskin Wealth Manage... Price $215.400 Owned Yes

7+

JOIN THE DISCUSSION
7 comments in the last 7 days

Stockchase, in its reporting on what has been discussed by indviduals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc. & Wealthica Financial Technology Inc.